Therefore, we next profiled the impact of NG-patch-controlled GLP-1 expression on experimental type 2 diabetes by treating type 2 diabetic mice bearing subcutaneously implanted HEKhNORM3 with clinically licensed NG patches for 35 days. Here, GLP1R is linked to type 2 diabetes mellitus.